MARKET

CRVO

CRVO

CervoMed
NASDAQ
3.310
+0.290
+9.60%
After Hours: 3.339 +0.029 +0.86% 18:34 10/05 EDT
OPEN
3.130
PREV CLOSE
3.020
HIGH
3.350
LOW
3.060
VOLUME
645.51K
TURNOVER
--
52 WEEK HIGH
10.00
52 WEEK LOW
2.130
MARKET CAP
50.04M
P/E (TTM)
-1.0310
1D
5D
1M
3M
1Y
5Y
1D
CervoMed Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 11h ago
Analysts Offer Insights on Healthcare Companies: CervoMed (CRVO), Genmab (GMAB) and Cytokinetics (CYTK)
TipRanks · 12h ago
Weekly Report: what happened at CRVO last week (0928-1002)?
Weekly Report · 12h ago
Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), Amylyx Pharmaceuticals Inc (AMLX) and CervoMed (CRVO)
TipRanks · 4d ago
3 Best Stocks to Buy Today, According to Top Wall Street Analysts – Sept. 29
TipRanks · 6d ago
Canaccord Genuity Sticks to Its Buy Rating for CervoMed (CRVO)
TipRanks · 6d ago
CervoMed Advances Neflamapimod Tablet and Dosing Strategy
TipRanks · 09/28 21:26
CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 mg BID Regimen; Buy Rating and $12 Price Target Reiterated
TipRanks · 09/28 14:45
More
About CRVO
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Webull offers CervoMed Inc stock information, including NASDAQ: CRVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRVO stock methods without spending real money on the virtual paper trading platform.